XML 20 R9.htm IDEA: XBRL DOCUMENT v3.25.3
REVENUES
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
REVENUES REVENUES
The Company’s Revenues by segment and by payers/customer groups were as follows:
Three Months Ended September 30, 2025Three Months Ended September 30, 2024
North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotal
Payer/Customer
Dx
   Clients23 %— %— %23 %24 %— %— %24 %
   Patients10 %— %— %10 %10 %— %— %10 %
   Medicare and Medicaid8 %— %— %8 %8 %— %— %8 %
   Third party37 %— %— %37 %36 %— %— %36 %
Total Dx revenues by payer78 %— %— %78 %78 %— %— %78 %
BLS
Pharmaceutical, biotechnology, and medical device companies9 %9 %4 %22 %9 %9 %4 %22 %
Total Revenues
87 %9 %4 %100 %87 %9 %4 %100 %
Nine Months Ended September 30, 2025Nine Months Ended September 30, 2024
North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotal
Payer/Customer
Dx
   Clients24 %— %— %24 %24 %— %— %24 %
   Patients10 %— %— %10 %10 %— %— %10 %
   Medicare and Medicaid8 %— %— %8 %8 %— %— %8 %
   Third party36 %— %— %36 %36 %— %— %36 %
Total Dx revenues by payer78 %— %— %78 %78 %— %— %78 %
BLS
Pharmaceutical, biotechnology, and medical device companies9 %9 %4 %22 %9 %9 %4 %22 %
Total Revenues87 %9 %4 %100 %87 %9 %4 %100 %
Revenues in the U.S. were $2,968.5 (83.3%) and $2,738.4 (83.4%) for the three months ended September 30, 2025, and 2024, respectively, and were $8,713.9 (83.5%) and $8,091.8 (83.6%) for the nine months ended September 30, 2025, and 2024, respectively.
Accounts Receivable, Unbilled Services, and Unearned Revenue
The following table provides information about accounts receivable, unbilled services, and unearned revenue from contracts with customers:
September 30, 2025December 31, 2024
Dx accounts receivable$1,398.8 $1,259.3 
BLS accounts receivable747.0 729.5 
Less: BLS allowance for credit losses(36.7)(44.7)
Accounts receivable, net$2,109.1 $1,944.1 
Gross unbilled services$162.8 $160.5 
Less: reserve for unbilled services(6.7)(7.6)
Unbilled services, net$156.1 $152.9 
Revenues recognized during the period that were included in the unearned revenue balance at the beginning of the period were $16.0 and $20.2 for the three months ended September 30, 2025, and 2024, respectively, and were $119.3 and $98.0 for the nine months ended September 30, 2025, and 2024, respectively.
Allowance for Credit Losses
BLS estimates future expected credit losses on Accounts receivable, net and Unbilled services, net over the remaining collection period of the instrument. The rollforward for the allowance for credit losses was as follows:
Accounts Receivable, netUnbilled Services, netTotal
Allowance for credit losses at December 31, 2024$44.7 $7.6 $52.3 
Credit loss expense1.1—1.1 
Write offs(10.8)(1.2)(12.0)
Foreign currency impact
1.7 0.3 2.0 
Allowance for credit losses at September 30, 2025$36.7 $6.7 $43.4